Intestinal microecology-based treatment for inflammatory bowel disease:Progress and prospects  

作　　者：Xia-Xiao Yan Dong Wu 

机构地区：[1]Department of Gastroenterology,State Key Laboratory of Complex Severe and Rare Diseases,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100730,China

出　　处：《World Journal of Clinical Cases》2023年第1期47-56,共10页世界临床病例杂志

基　　金：Supported by CAMS Innovation Fund for Medical Sciences,No.2022-I2M-1-003。

摘　　要：Inflammatory bowel disease(IBD)is a chronic,recurrent,and debilitating disorder,and includes Crohn’s disease and ulcerative colitis.The pathogenesis of IBD is closely associated with intestinal dysbiosis,but has not yet been fully clarified.Genetic and environmental factors can influence IBD patients’gut microbiota and metabolism,disrupt intestinal barriers,and trigger abnormal immune responses.Studies have reported the alteration of gut microbiota and metabolites in IBD,providing the basis for potential therapeutic options.Intestinal microbiota-based treatments such as pre/probiotics,metabolite supplementation,and fecal microbiota transplantation have been extensively studied,but their clinical efficacy remains controversial.Repairing the intestinal barrier and promoting mucosal healing have also been proposed.We here review the current clinical trials on intestinal microecology and discuss the prospect of research and practice in this field.

关 键 词：Inflammatory bowel disease PROBIOTICS PREBIOTICS Intestinal metabolites Fecal microbiota transplantation Intestinal barrier 

分 类 号：R574[医药卫生—消化系统]